Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CRESCENT BIOPHARMA, INC.

Get SEC filing alerts via email and in your feed for CRESCENT BIOPHARMA, INC.

CBIO

CRESCENT BIOPHARMA, INC.

About CRESCENT BIOPHARMA, INC.

GlycoMimetics, Inc. is a biotechnology company specializing in glycomimetic small molecules that target carbohydrate-related biological processes. Its focus includes developing therapies for cancers and inflammatory diseases, with a pipeline centered on selectin antagonists like uproleselan. The company collaborates globally, holds key patents, and relies on third-party manufacturing, aiming to address high unmet medical needs through innovative, proprietary drug candidates.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CRESCENT BIOPHARMA, INC.

1
1
CRESCENT BIOPHARMA, INC. Crescent Biopharma Reports $23.3 Million Net Loss and First Revenue Generation in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
CRESCENT BIOPHARMA, INC. Crescent Biopharma Reports Fiscal Year 2025 Results and Strategic Advances

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CRESCENT BIOPHARMA, INC. Crescent Biopharma Reports $24.6 Million Net Loss in Latest Quarter, Focuses on CR-001 Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CRESCENT BIOPHARMA, INC. Crescent Biopharma Reports $21.8 Million Net Loss and Significant Asset Growth in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CRESCENT BIOPHARMA, INC. GlycoMimetics Reports Reduced Losses and Restructuring Ahead of Merger

Via official filing (AI summary) | about 1 year ago | 0 comments